Evaluation of antifibrotic and antifungal combined therapies in experimental pulmonary paracoccidioidomycosis

Detalhes bibliográficos
Autor(a) principal: Finato, Angela C. [UNESP]
Data de Publicação: 2020
Outros Autores: Almeida, Débora F [UNESP], Dos Santos, Amanda R. [UNESP], Nascimento, Dejair C., Cavalcante, Ricardo S. [UNESP], Mendes, Rinaldo P. [UNESP], Soares, Cléverson T, Paniago, Anamaria M M, Venturini, James
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1093/mmy/myz100
http://hdl.handle.net/11449/199069
Resumo: Paracoccidioidomycosis (PCM) is a systemic mycosis caused by the Paracoccidioides genus. Most of the patients with chronic form present sequelae, like pulmonary fibrosis, with no effective treatment, leading to impaired lung functions. In the present study, we aimed to investigate the antifibrotic activity of three compounds: pentoxifylline (PTX), azithromycin (AZT), and thalidomide (Thal) in a murine model of pulmonary PCM treated with itraconazole (ITC) or cotrimoxazole (CMX). BALB/c mice were inoculated with P. brasiliensis (Pb) by the intratracheal route and after 8 weeks, they were submitted to one of the following six treatments: PTX/ITC, PTX/CMX, AZT/ITC, AZT/CMX, Thal/ITC, and Thal/CMX. After 8 weeks of treatment, the lungs were collected for determination of fungal burden, production of OH-proline, deposition of reticulin fibers, and pulmonary concentrations of cytokines and growth factors. Pb-infected mice treated with PTX/ITC presented a reduction in the pulmonary concentrations of OH-proline, associated with lower concentrations of interleukin (IL)-6, IL-17, and transforming growth factor (TGF)-β1 and higher concentrations of IL-10 compared to the controls. The Pb-infected mice treated with AZT/CMX exhibited decreased pulmonary concentrations of OH-proline associated with lower levels of TGF-β1, and higher levels of IL-10 compared controls. The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-γ and VEGF, and decreased concentrations of IL-6, IL-1β, IL-17, and TGF-β1. In conclusion, our findings reinforce the antifibrotic role of PTX only when associated with ITC, and AZT only when associated with CMX, but Thal did not show any action upon addition.
id UNSP_28feadde1bc3fcb12a2675386eba1bc1
oai_identifier_str oai:repositorio.unesp.br:11449/199069
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Evaluation of antifibrotic and antifungal combined therapies in experimental pulmonary paracoccidioidomycosisParacoccidioides brasiliensisazithromycincotrimoxazoleitraconazolepentoxifyllinepulmonary fibrosisthalidomideParacoccidioidomycosis (PCM) is a systemic mycosis caused by the Paracoccidioides genus. Most of the patients with chronic form present sequelae, like pulmonary fibrosis, with no effective treatment, leading to impaired lung functions. In the present study, we aimed to investigate the antifibrotic activity of three compounds: pentoxifylline (PTX), azithromycin (AZT), and thalidomide (Thal) in a murine model of pulmonary PCM treated with itraconazole (ITC) or cotrimoxazole (CMX). BALB/c mice were inoculated with P. brasiliensis (Pb) by the intratracheal route and after 8 weeks, they were submitted to one of the following six treatments: PTX/ITC, PTX/CMX, AZT/ITC, AZT/CMX, Thal/ITC, and Thal/CMX. After 8 weeks of treatment, the lungs were collected for determination of fungal burden, production of OH-proline, deposition of reticulin fibers, and pulmonary concentrations of cytokines and growth factors. Pb-infected mice treated with PTX/ITC presented a reduction in the pulmonary concentrations of OH-proline, associated with lower concentrations of interleukin (IL)-6, IL-17, and transforming growth factor (TGF)-β1 and higher concentrations of IL-10 compared to the controls. The Pb-infected mice treated with AZT/CMX exhibited decreased pulmonary concentrations of OH-proline associated with lower levels of TGF-β1, and higher levels of IL-10 compared controls. The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-γ and VEGF, and decreased concentrations of IL-6, IL-1β, IL-17, and TGF-β1. In conclusion, our findings reinforce the antifibrotic role of PTX only when associated with ITC, and AZT only when associated with CMX, but Thal did not show any action upon addition.Faculdade de Ciências. Universidade Estadual Paulista (UNESP)MS, Faculdade de Medicina (FAMED). Universidade Federal do Mato Grosso do Sul (UFMS). 79070-900 Campo GrandeInstituto Lauro de Souza Lima (ILSL)Faculdade de Medicina de Botucatu. Universidade Estadual Paulista (UNESP)Faculdade de Ciências. Universidade Estadual Paulista (UNESP)Faculdade de Medicina de Botucatu. Universidade Estadual Paulista (UNESP)Universidade Estadual Paulista (Unesp)Universidade Federal de Mato Grosso do Sul (UFMS)Instituto Lauro de Souza Lima (ILSL)Finato, Angela C. [UNESP]Almeida, Débora F [UNESP]Dos Santos, Amanda R. [UNESP]Nascimento, Dejair C.Cavalcante, Ricardo S. [UNESP]Mendes, Rinaldo P. [UNESP]Soares, Cléverson TPaniago, Anamaria M MVenturini, James2020-12-12T01:29:58Z2020-12-12T01:29:58Z2020-07-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article667-678http://dx.doi.org/10.1093/mmy/myz100Medical mycology, v. 58, n. 5, p. 667-678, 2020.1460-2709http://hdl.handle.net/11449/19906910.1093/mmy/myz1002-s2.0-85087465833Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengMedical mycologyinfo:eu-repo/semantics/openAccess2021-10-23T02:54:13Zoai:repositorio.unesp.br:11449/199069Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462021-10-23T02:54:13Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Evaluation of antifibrotic and antifungal combined therapies in experimental pulmonary paracoccidioidomycosis
title Evaluation of antifibrotic and antifungal combined therapies in experimental pulmonary paracoccidioidomycosis
spellingShingle Evaluation of antifibrotic and antifungal combined therapies in experimental pulmonary paracoccidioidomycosis
Finato, Angela C. [UNESP]
Paracoccidioides brasiliensis
azithromycin
cotrimoxazole
itraconazole
pentoxifylline
pulmonary fibrosis
thalidomide
title_short Evaluation of antifibrotic and antifungal combined therapies in experimental pulmonary paracoccidioidomycosis
title_full Evaluation of antifibrotic and antifungal combined therapies in experimental pulmonary paracoccidioidomycosis
title_fullStr Evaluation of antifibrotic and antifungal combined therapies in experimental pulmonary paracoccidioidomycosis
title_full_unstemmed Evaluation of antifibrotic and antifungal combined therapies in experimental pulmonary paracoccidioidomycosis
title_sort Evaluation of antifibrotic and antifungal combined therapies in experimental pulmonary paracoccidioidomycosis
author Finato, Angela C. [UNESP]
author_facet Finato, Angela C. [UNESP]
Almeida, Débora F [UNESP]
Dos Santos, Amanda R. [UNESP]
Nascimento, Dejair C.
Cavalcante, Ricardo S. [UNESP]
Mendes, Rinaldo P. [UNESP]
Soares, Cléverson T
Paniago, Anamaria M M
Venturini, James
author_role author
author2 Almeida, Débora F [UNESP]
Dos Santos, Amanda R. [UNESP]
Nascimento, Dejair C.
Cavalcante, Ricardo S. [UNESP]
Mendes, Rinaldo P. [UNESP]
Soares, Cléverson T
Paniago, Anamaria M M
Venturini, James
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (Unesp)
Universidade Federal de Mato Grosso do Sul (UFMS)
Instituto Lauro de Souza Lima (ILSL)
dc.contributor.author.fl_str_mv Finato, Angela C. [UNESP]
Almeida, Débora F [UNESP]
Dos Santos, Amanda R. [UNESP]
Nascimento, Dejair C.
Cavalcante, Ricardo S. [UNESP]
Mendes, Rinaldo P. [UNESP]
Soares, Cléverson T
Paniago, Anamaria M M
Venturini, James
dc.subject.por.fl_str_mv Paracoccidioides brasiliensis
azithromycin
cotrimoxazole
itraconazole
pentoxifylline
pulmonary fibrosis
thalidomide
topic Paracoccidioides brasiliensis
azithromycin
cotrimoxazole
itraconazole
pentoxifylline
pulmonary fibrosis
thalidomide
description Paracoccidioidomycosis (PCM) is a systemic mycosis caused by the Paracoccidioides genus. Most of the patients with chronic form present sequelae, like pulmonary fibrosis, with no effective treatment, leading to impaired lung functions. In the present study, we aimed to investigate the antifibrotic activity of three compounds: pentoxifylline (PTX), azithromycin (AZT), and thalidomide (Thal) in a murine model of pulmonary PCM treated with itraconazole (ITC) or cotrimoxazole (CMX). BALB/c mice were inoculated with P. brasiliensis (Pb) by the intratracheal route and after 8 weeks, they were submitted to one of the following six treatments: PTX/ITC, PTX/CMX, AZT/ITC, AZT/CMX, Thal/ITC, and Thal/CMX. After 8 weeks of treatment, the lungs were collected for determination of fungal burden, production of OH-proline, deposition of reticulin fibers, and pulmonary concentrations of cytokines and growth factors. Pb-infected mice treated with PTX/ITC presented a reduction in the pulmonary concentrations of OH-proline, associated with lower concentrations of interleukin (IL)-6, IL-17, and transforming growth factor (TGF)-β1 and higher concentrations of IL-10 compared to the controls. The Pb-infected mice treated with AZT/CMX exhibited decreased pulmonary concentrations of OH-proline associated with lower levels of TGF-β1, and higher levels of IL-10 compared controls. The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-γ and VEGF, and decreased concentrations of IL-6, IL-1β, IL-17, and TGF-β1. In conclusion, our findings reinforce the antifibrotic role of PTX only when associated with ITC, and AZT only when associated with CMX, but Thal did not show any action upon addition.
publishDate 2020
dc.date.none.fl_str_mv 2020-12-12T01:29:58Z
2020-12-12T01:29:58Z
2020-07-01
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1093/mmy/myz100
Medical mycology, v. 58, n. 5, p. 667-678, 2020.
1460-2709
http://hdl.handle.net/11449/199069
10.1093/mmy/myz100
2-s2.0-85087465833
url http://dx.doi.org/10.1093/mmy/myz100
http://hdl.handle.net/11449/199069
identifier_str_mv Medical mycology, v. 58, n. 5, p. 667-678, 2020.
1460-2709
10.1093/mmy/myz100
2-s2.0-85087465833
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Medical mycology
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 667-678
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1803046849627553792